REV-ERBα regulates brain NAD+ levels and tauopathy via an NFIL3–CD38 axis
8.5
来源：
Nature
资金机构：
National Institute on Aging; Cure Alzheimer’s Fund; McDonnell Center for Cellular and Molecular Neurobiology; National Research Foundation of Korea; Korean Ministry of Science and ICT; National Institutes of Health; National Cancer Institute; Siteman Cancer Center; National Center for Research Resources; Diabetes Research Center; Institute of Clinical and Translational Sciences; NCATS; Mass Spectrometry Technology Access Center
发布时间：
2025-09-01 23:36
摘要：
REV-ERBα regulates brain NAD+ levels through an NFIL3–CD38 axis, with deletion of REV-ERBα shown to augment NAD+ levels and prevent tauopathy in P301S mice. This study highlights the potential of targeting REV-ERBα as a therapeutic strategy for Alzheimer's disease, suggesting that pharmacological inhibition may offer protective effects against tau-mediated neurodegeneration.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
0.5
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.5
关键证据
REV-ERBα deletion augments brain NAD+ and prevents tauopathy in P301S mice.
The NFIL3–CD38 pathway controls brain NAD+ metabolism and neurodegeneration.
Pharmacological antagonism of REV-ERBα can mitigate tau pathology in PS19 mice.
真实性检查
否
AI评分总结
REV-ERBα regulates brain NAD+ levels through an NFIL3–CD38 axis, with deletion of REV-ERBα shown to augment NAD+ levels and prevent tauopathy in P301S mice. This study highlights the potential of targeting REV-ERBα as a therapeutic strategy for Alzheimer's disease, suggesting that pharmacological inhibition may offer protective effects against tau-mediated neurodegeneration.